On Jan.2, 2007, Merck announced that it had completed its acquisition of Sirna Therapeutics for $1.1 billion in cash. Ribozyme Pharma was founded in Boulder in 1992 with a focus on the broad potential of ribozymes for use in the development of human therapeutics and other areas and in the identification of gene function.